{"id":282309,"date":"2026-01-13T17:24:08","date_gmt":"2026-01-13T17:24:08","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/282309\/"},"modified":"2026-01-13T17:24:08","modified_gmt":"2026-01-13T17:24:08","slug":"illumina-unveils-dataset-to-speed-up-ai-powered-drug-discovery","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/282309\/","title":{"rendered":"Illumina unveils dataset to speed up AI-powered drug discovery"},"content":{"rendered":"\n<p class=\"yf-vbsvxt\">Jan 13 (Reuters) &#8211; Gene sequencing company Illumina on Tuesday introduced a dataset that maps genetic changes to help \u200baccelerate drug discovery through <a href=\"https:\/\/tech.yahoo.com\/ai\/\" data-ylk=\"slk:artificial intelligence;elm:context_link;itc:0;sec:content-canvas\" class=\"link \" rel=\"nofollow noopener\" target=\"_blank\">artificial intelligence<\/a>.<\/p>\n<p class=\"yf-vbsvxt\">The company said \u200cit was partnering with drugmakers AstraZeneca, Merck and Eli Lilly for its Billion \u200cCell Atlas, which will train advanced AI models at scale and advance research into fundamental disease mechanisms that have previously been out of reach.<\/p>\n<p class=\"yf-vbsvxt\">Drug developers are increasingly adopting AI for discovery \u2060and safety testing \u200cto get faster and cheaper results, in line with the U.S. Food and Drug Administration&#8217;s push \u200dto reduce animal testing in the near future.<\/p>\n<p class=\"yf-vbsvxt\">Drug development software maker Certara and biotechs such as Schrodinger and Recursion Pharmaceuticals are using the \u200bbooming technology to predict how experimental drugs might be \u200cabsorbed, distributed or trigger toxic side-effects.<\/p>\n<p class=\"yf-vbsvxt\">&#8220;We believe the Cell Atlas is a key development that will enable us to significantly scale AI for drug discovery,&#8221; said Illumina CEO Jacob Thaysen.<\/p>\n<p class=\"yf-vbsvxt\">The Atlas will capture how 1 billion individual cells respond to \u2060genetic changes via CRISPR across more \u200bthan 200 disease-relevant cell lines.<\/p>\n<p class=\"yf-vbsvxt\">These cell \u200blines have been selected for their relevance to diseases, many of which have been historically difficult to \u200ddecode, including immune \u2060disorders and cancer as well as cardiometabolic, neurological and rare genetic diseases.<\/p>\n<p class=\"yf-vbsvxt\">The Atlas will enable users to characterize \u2060drug and disease mechanisms of action, explore potential new indications and validate \u200ccandidate targets from human genetics.<\/p>\n<p class=\"yf-vbsvxt\">(Reporting by Christy Santhosh in \u200cBengaluru; Editing by Shilpi Majumdar)<\/p>\n","protected":false},"excerpt":{"rendered":"Jan 13 (Reuters) &#8211; Gene sequencing company Illumina on Tuesday introduced a dataset that maps genetic changes to&hellip;\n","protected":false},"author":2,"featured_media":282310,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[261],"tags":[291,289,290,90555,4948,3541,18,142170,142169,19,141664,17,82],"class_list":{"0":"post-282309","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-artificial-intelligence","8":"tag-ai","9":"tag-artificial-intelligence","10":"tag-artificialintelligence","11":"tag-cell-atlas","12":"tag-discovery","13":"tag-drug-discovery","14":"tag-eire","15":"tag-gene-sequencing","16":"tag-genetic-changes","17":"tag-ie","18":"tag-illumina","19":"tag-ireland","20":"tag-technology"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/115888958035845237","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/282309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=282309"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/282309\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/282310"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=282309"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=282309"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=282309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}